Enochian BioSciences, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Enochian BioSciences, Inc. (NASDAQ: ENOB) between January 17, 2018 and June 27, 2022, both dates inclusive (the “Class Period”), including common stock issued by Enochian in a private placement offering on or about February 16, 2018. If you wish to serve as lead plaintiff, you must move the Court no later than September 26, 2022.

If you purchased Enochian BioSciences securities and would like to join the  action, please click “Join This Class Action.”

集体诉讼期:September 24, 2020 through May 31, 2022
If you purchased Enochian BioSciences securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.


According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:

  • Co-founder and inventor, Serhat Gumrukcu, was engaged in a variety of frauds;
  • Gumrukcu was not a licensed doctor anywhere in the world;
  •  Gumrukcu’s purported contributions to Enochian lacked a reasonable basis;
  • Enochian had overstated its commercial prospects;
  • Gumrukcu had improperly diverted approximately $20 million from Enochian to entities he owned; and
  • Defendants’ positive statements about Enochian’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis Serhat Gumrukçu, the inventor and co-founder of Enochian BioSciences, was not a licensed doctor and had no verifiable degrees beyond high school;
  • accordingly, the scientific and technological underpinnings of Enochian BioSciences’ product pipeline, purportedly invented by Gumrukçu, were dubious at best;
  • accordingly, the defendants had significantly overstated the commercial prospects for the Company’s product pipeline;
  • Enochian BioSciences’ senior leadership knew Gumrukçuhad a criminal history that included fraud;
  • accordingly, Enochian BioScience’ reliance on Gumrukçu, and its consulting and licensing agreements with G-Tech Bio, LLC and Seraph Research Institute (“SRI”), both of which are controlled by Gumrukçu, subjected the Company to a heightened risk  of reputational and financial harm, as well as threatened the integrity of the Company’s scientific findings; and
  • As a result, the Company’s public statements were materially false and misleading at all relevant times.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.

公司名称: Enochian Biosciences, Inc.
股票代号: ENOB
集体诉讼期: January 17, 2018 through June 27, 2022,
法院: United States District Court for the Central District of California


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。